Sino Biopharmaceutical Limited (HKG:1177)
4.975
-0.375 (-7.01%)
Oct 22, 2026, 2:05 PM HKT
Sino Biopharmaceutical Revenue
Sino Biopharmaceutical had revenue of 19.44B CNY in the half year ending June 30, 2026, with 22.49% growth. This brings the company's total for the last twelve months to 33.70B, up 10.26% year-over-year. In the year 2025, Sino Biopharmaceutical had annual revenue of 31.83B with 10.28% growth. That makes Sino Biopharmaceutical the 2,631st largest company in the world by revenue and 175th in Hong Kong.
Revenue (ttm)
33.70B CNY
Revenue Growth
+10.26%
P/S Ratio
2.45
Revenue / Employee
1.48M CNY
Employees
22,838
Market Cap
88.60B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.83B | 2.97B | 10.28% |
| Dec 31, 2024 | 28.87B | 2.67B | 10.18% |
| Dec 31, 2023 | 26.20B | 173.25M | 0.67% |
| Dec 31, 2022 | 26.03B | -835.19M | -3.11% |
| Dec 31, 2021 | 26.86B | 3.21B | 13.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| WuXi Biologics | 27.27B |
| 3SBio | 20.63B |
| Innovent Biologics | 18.13B |
| RemeGen | 9.24B |
| Shanghai Henlius Biotech | 8.58B |
| Genscript Biotech | 6.63B |
| Akeso | 3.98B |
| Shanghai Junshi Biosciences | 3.49B |
Sino Biopharmaceutical News
- 2 days ago - Transcenta Appoints Former Sino Biopharmaceutical CFO Jennie Ma - Nasdaq
- 2 months ago - Sino Biopharmaceutical Limited Unveils New Global Brand, SBP Group, to Accelerate International Expansion - PRNewsWire
- 2 months ago - Sino Biopharmaceutical Earnings release: H1 2026 - Filings
- 2 months ago - Sino Biopharmaceutical Quarterly report: H1 2026 - Filings
- 3 months ago - Sino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugs - Reuters
- 3 months ago - AstraZeneca, Sino Biopharm Sign Up to $1.9 Billion Respiratory Drug Licensing Deal - WSJ
- 3 months ago - Hong Kong-listed Sino Biopharma, AstraZeneca sign respiratory drug deal worth up to $1.9 billion - Reuters
- 5 months ago - GSK enters into exclusive strategic collaboration with Sino Biopharm - TheFly